Technetium (99mTc) Macroaggregated Human Serum Albumin(Technetium (99mTc) Macroaggregated Human Serum Albumin)

概要

基本信息

药物类型

化学药、诊断用放射药物

别名

Techne MAA

+ [1]

靶点-

作用方式-

作用机制-

治疗领域

心血管疾病呼吸系统疾病肿瘤

在研适应症

肺血管疾病肺癌

非在研适应症-

原研机构

PDRadiopharma, Inc.

在研机构

PDRadiopharma, Inc.

Mass General Brigham, Inc.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1977-06-14),

肺血管疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的临床试验

NL-OMON55138

/ CompletedN/AIIT

IXSI: Interventional X-ray and Scintigraphy Imaging of 99mTc-MAA during the radioembolisation pretreatment procedure - IXSI

开始日期2021-05-25

申办/合作机构-

NL-OMON23992

/ RecruitingN/AIIT

IXSI: Interventional X-ray and Scintigraphy Imaging of 99mTc-MAA during the radioembolisation pretreatment procedure

开始日期2021-05-01

申办/合作机构

University Medical Center of Utrecht

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的临床结果

登录后查看更多信息

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的转化医学

登录后查看更多信息

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的专利（医药）

登录后查看更多信息

77

项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的文献（医药）

2025-03-01·Cirugía Española (English Edition)

Radioguided parathyroidectomy: How does it contribute to surgery?

Article

作者: Redondo Expósito, Aitor ; Salvador Egea, Pilar ; Pérez Otermin, Irati ; Erce García, Cristina ; Anda Apiñániz, Emma ; Blanco Saiz, Isabel ; Cruz Vásquez, Naomi

OBJECTIVETo evaluate whether a radioguided approach allows a higher intraoperative detection rate of adenoma and a minimally invasive parathyroidectomy (MIP), with the same or better cure rate of hyperparathyroidism secondary to parathyroid adenoma.METHODSThis was an observational, prospective, single-center study involving 254 consecutive patients with primary hyperparathyroidism, between 2017 and 2022. A total of 258 procedures were performed: 129 non radioguided (NRS) and 129 radioguided (RS) (112 with intravenous 99mTc- MIBI and 17 with ultrasound-guided intralesional 99mTc-MAA injection) with an intraoperative gamma probe and gamma camera. Follow-up was performed for at least one year.RESULTSThere were no differences between the groups in terms of age, sex, preoperative calcium or parathyroid hormone levels, adenoma localization with 99mTc-MIBI-gammagraphy and ultrasound, and surgical morbidity. Intraoperative surgical localization was 97.7% in both groups. Statistically significant differences supported RS: It allowed to perform MIP (RS: 96.9%, NRS 88.4%; p = 0.015), also in patients with previous neck surgery (RS: 75%, NRS: 28%; p = 0.019) and with ectopic adenomas (RS: 93.3%, NRS: 71.4%; p = 0.012). The operative time was significantly shorter (RS: 51 min, NRS: 59.79 min; p = 0.005). There were no significant differences in the postoperative complications between the groups. Biochemical cure at six months was achieved in RS: 97.7% and NRS: 93.8% (p = 0.12).CONCLUSIONSRadioguided MIP is useful in ectopic adenomas and in patients with previous cervical surgery and allows a minimally invasive approach more frequently. It is a safe surgery, easily reproducible by an endocrine surgeon and requires usual equipment found in operating rooms.

2024-03-01·Annals of Nuclear Medicine

Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing 99mTc-MAA and 90Y-microspheres radioembolization

Article

作者: Khamwan, Kitiwat ; Sukprakun, Chanan ; Siricharoen, Punnarai ; Noipinit, Nut

PURPOSEThis study aimed to determine the absorbed doses in the tumoral-liver and non-tumoral liver of hepatocellular carcinoma (HCC) patients undergoing radioembolization with Yttrium-90 (⁹⁰Y) resin microspheres, and compared with those derived from ^99mTc-MAA using the partition model.METHODSA total of 42 HCC patients (28 males and 14 females, mean age 65 ± 11.51 years) who received 45 treatment sessions with ⁹⁰Y-microspheres between 2016 and 2021 were included. Pre-treatment ^99mTc-MAA and post-treatment ⁹⁰Y-bremsstrahlung SPECT/CT were acquired for each patient. Semi-automated segmentation of regions of interest (ROIs) was performed using MIM Encore software to determine the tumor-liver ratio (TLR) encompassing the liver volume, tumoral-liver, and lungs, and verified by both nuclear medicine physician and interventional radiologist. A partition dosimetry model was used to estimate the administered activity of ⁹⁰Y-microspheres and the absorbed doses to the tumoral-liver and non-tumoral liver. The student's paired t test and Bland-Altman plot were used for the statistical analysis.RESULTSThe mean TLR values obtained from ^99mTc-MAA SPECT/CT and ⁹⁰Y-bremsstrahlung SPECT/CT were 4.78 ± 3.51 and 2.73 ± 1.18, respectively. The mean planning administered activity of ⁹⁰Y-microspheres based on ^99mTc-MAA SPECT/CT was 1.56 ± 0.80 GBq, while the implanted administered activity was 2.53 ± 1.23 GBq (p value < 0.001). The mean absorbed doses in the tumoral-liver estimated from ^99mTc-MAA and ⁹⁰Y-bremsstrahlung SPECT/CT were 127.44 ± 4.36 Gy and 135.98 ± 6.30 Gy, respectively. The corresponding mean absorbed doses in the non-tumoral liver were 34.61 ± 13.93 Gy and 55.04 ± 16.36 Gy.CONCLUSIONThis study provides evidence that the administered activity of ⁹⁰Y-microspheres, as estimated from ⁹⁰Y-bremsstrahlung SPECT/CT, was significantly higher than that estimated from ^99mTc-MAA SPECT/CT resulted in increased absorbed doses in both the tumoral-liver and non-tumoral liver. However, ^99mTc-MAA SPECT/CT remains a valuable planning tool for predicting the distribution of ⁹⁰Y-microspheres in liver cancer treatment.

2023-01-01·Japanese Journal of Radiological Technology

<sup>99m</sup>Tc-macro aggregated albumin（MAA）投与時におけるシリンジと投与ルートの残留率評価—小児核医学検査を想定した低液量での検討—

Article

作者: Shibata, Shigeru ; Mimura, Hiroaki ; Inubushi, Masayuki ; Kangai, Yoshiharu ; Sato, Shun ; Nakamura, Yuto ; Abe, Toshinori

PURPOSEThe purpose of this study was to evaluate the residual radioactivity in the syringe and route of administration of a low fluid volume ^99mTc-macro aggregated albumin (MAA) intended for pediatric nuclear medicine examinations.METHODWe evaluated the residual characteristics, as the effect of elapsed time from drawing up of radiopharmaceuticals to plastic syringe to administration, and the effect of volume of ^99mTcO₄^- solution to be labeled, the effect of rinsed times of plastic syringe, effect of dose of calculated by consensus guidelines for pediatric nuclear medicine and residual location in injection sets with ^99mTc-MAA. Residual radioactivity was measured using planar images obtained by the gamma camera.RESULTSResidual radioactivity rate of ^99mTc-MAA, ^99mTc-MAG₃, ¹²³I-IMP showed 41.3±1.6%, 14.4±0.6%, 14.6±2.0%, respectively. ^99mTc-MAA clearly showed a higher residual rate. Residual radioactivity rate increased with the extension of the elapsed time, and reached a high value of 41.3% in 30 minutes. Residual radioactivity rate was dependent on the different volume of ^99mTcO₄^- to be labeled (4.0 ml and 8.0 ml). Residual radioactivity rate did not change when the number of rinsed was more than one. Residual rate was around 40% at all doses of calculated by consensus guidelines for pediatric nuclear medicine.CONCLUSION^99mTc-MAA showed the highest residual radioactivity rate among radiopharmaceuticals used in pediatric nuclear medicine examinations. The factor that most affected the residual radioactivity rate of ^99mTc-MAA was the elapsed time from draw up to the plastic syringe to administration.

100 项与 Technetium (99mTc) Macroaggregated Human Serum Albumin 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肺血管疾病	日本	PDRadiopharma, Inc.	1977-06-14

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺癌	临床1期	-	Mass General Brigham, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2024	N/A	-	-	99mTc-MAA (90Y-Microspheres PET/CT)	憲繭製觸鏇選選構範選(製蓋積顧構淵壓壓製遞) = D50 values displayed a strong correlation between planned and administered doses 繭廠製遞觸襯糧艱廠鹹 (憲壓願窪蓋淵齋衊齋膚 ) 更多	-	2024-06-09
SNMMI2024	N/A	-	-	99mTc-MAAsphere Radioembolization (99mTc-MAA planar and SPECT/CT)	鏇鏇簾遞選衊顧觸夢廠(構淵獵顧顧壓窪網築糧) = 範構廠簾網襯壓鏇夢醖糧襯憲鑰積齋顧衊觸醖 (選襯衊齋齋鏇鹽製築齋 )	-	2024-06-09
				90Y-Microsphere Radioembolization (90Y-microsphere SPECT/CT and PET/CT)	鏇鏇簾遞選衊顧觸夢廠(構淵獵顧顧壓窪網築糧) = 夢廠繭窪鏇遞壓餘衊憲糧襯憲鑰積齋顧衊觸醖 (選襯衊齋齋鏇鹽製築齋 )
EANM2022	N/A	-	-	99mTc-MAA (MAA1)	淵願獵鬱廠壓遞鹽範膚(顧廠衊窪願範構憲簾網) = 艱簾夢廠廠網齋窪壓蓋簾夢鹽顧蓋膚齋膚糧繭 (顧憲鏇淵憲齋鑰選膚鏇 )	-	2022-09-22
TARGET phantom study (EANM2022)	N/A	-	-	99m Tc MAA (Standardized Protocol)	簾鹽憲夢鹹壓築顧糧膚(糧鏇構觸淵繭鏇簾夢鬱) = 窪憲憲窪憲願製鑰衊觸願餘壓製窪鏇簾襯鏇淵 (鬱夢築鹹淵遞襯襯獵淵, 0.82)	-	2022-09-22
				99m Tc MAA (Site-Specific Protocol)	簾鹽憲夢鹹壓築顧糧膚(糧鏇構觸淵繭鏇簾夢鬱) = 蓋製築窪餘選壓艱壓繭願餘壓製窪鏇簾襯鏇淵 (鬱夢築鹹淵遞襯襯獵淵 )
TARGET Round Robin sub-study (EANM2022)	N/A	肝细胞癌 90 Y glass microspheres	20	Yttrium-90 (Anatomic workflow)	淵餘範網憲醖衊醖鏇顧(選網遞襯製積餘構製餘) = 選衊範獵夢衊簾襯淵壓遞積衊鹹糧選構鬱廠廠 (獵淵鹹願餘憲憲鑰襯顧 ) 更多	-	2022-09-22
				Yttrium-9099m Tc-MAA (99m Tc-MAA SPECT workflow)	淵餘範網憲醖衊醖鏇顧(選網遞襯製積餘構製餘) = 顧鏇觸夢觸廠憲積窪窪遞積衊鹹糧選構鬱廠廠 (獵淵鹹願餘憲憲鑰襯顧 ) 更多
TARGET Study99m Tc-MAA (EANM2022)	N/A	肝细胞癌	209	Y-90 Glass Microspheres (Anatomic Workflow)	(鏇網構餘鏇襯鹹餘膚衊): odds ratio = 1.22 (95% CI, 1.01 ~ 1.49), P-Value = 0.044 更多	-	2022-09-22
				Y-90 Glass Microspheres99m Tc-MAA Microspheres (99m Tc-MAA SPECT Workflow)
EANM2019	N/A	终末期肾脏病	8	99m Tc-MAA (Patients with Peritoneal Leakage)	餘觸蓋網遞衊膚鑰獵壓(選艱醖構遞餘淵鬱鹹鏇) = 糧襯製鏇顧鏇壓餘襯夢鹽築獵選鬱艱範壓膚壓 (遞遞衊壓觸鑰憲鑰衊鑰 )	-	2019-09-18
SNMMI2019	N/A	-	50	99mTc-MAA (Planar scintigraphy)	簾襯顧淵憲願網壓餘顧(網繭夢醖襯顧窪艱鹹蓋) = 選淵壓淵願艱醖願觸醖糧遞膚製齋齋襯蓋簾顧 (願齋遞醖獵顧膚鑰夢製, 1.1 ~ 32.6)	积极	2019-05-21
				99mTc-MAA (SPECT/CT)	簾襯顧淵憲願網壓餘顧(網繭夢醖襯顧窪艱鹹蓋) = 觸窪網壓繭鹽鏇壓齋餘糧遞膚製齋齋襯蓋簾顧 (願齋遞醖獵顧膚鑰夢製, 1.3 ~ 21.2)
SNMMI2019	N/A	肿瘤	-	99mTc-MAA	襯築繭餘獵膚獵簾網膚(顧窪餘簾衊網糧構鏇簾) = 壓鏇遞夢範鬱夢鬱構範衊選願窪簾願遞憲鹹製 (齋願廠遞醖憲憲餘憲壓 ) 更多	-	2019-05-21
				99mTc-MAA (90Y-microspheres)	襯築繭餘獵膚獵簾網膚(顧窪餘簾衊網糧構鏇簾) = 製餘築淵憲蓋衊蓋襯糧衊選願窪簾願遞憲鹹製 (齋願廠遞醖憲憲餘憲壓 ) 更多
EANM2018	N/A	-	20	99m Tc-MAA (90 Y-TheraSphere)	選糧簾繭獵醖膚膚鬱觸(壓夢膚膚餘鬱膚鹽壓膚) = 糧淵艱觸簾夢窪簾觸範膚顧製鏇繭構獵襯艱餘 (憲襯齋齋襯獵積選積餘 ) 更多	积极	2018-09-18